About silence therapeutics - SLN
Silence Therapeutics Plc engages in the discovery, delivery, and development of ribonucleic acid (RNA) therapeutics. It also develops medicines by harnessing the body's natural mechanism of RNA interference within its cells. The company was founded on November 18, 1994 and is headquartered in London, the United Kingdom.
SLN At a Glance
Silence Therapeutics Plc
12 Hammersmith Grove
London, Greater London W6 7AP
| Phone | 44-20-3457-6900 | Revenue | 560.31K | |
| Industry | Miscellaneous Commercial Services | Net Income | -88,819,074.79 | |
| Sector | Commercial Services | Employees | 88 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
SLN Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 512.52 |
| Price to Book Ratio | 4.609 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -2.468 |
| Enterprise Value to Sales | 360.899 |
| Total Debt to Enterprise Value | 0.001 |
SLN Efficiency
| Revenue/Employee | 6,367.117 |
| Income Per Employee | -1,009,307.668 |
| Receivables Turnover | 0.023 |
| Total Asset Turnover | 0.003 |
SLN Liquidity
| Current Ratio | 8.717 |
| Quick Ratio | 8.717 |
| Cash Ratio | 6.252 |
SLN Profitability
| Gross Margin | -9.839 |
| Operating Margin | -14,720.93 |
| Pretax Margin | -15,849.911 |
| Net Margin | -15,851.878 |
| Return on Assets | -53.173 |
| Return on Equity | -90.481 |
| Return on Total Capital | -142.192 |
| Return on Invested Capital | -90.448 |
SLN Capital Structure
| Total Debt to Total Equity | 0.257 |
| Total Debt to Total Capital | 0.256 |
| Total Debt to Total Assets | 0.122 |
| Long-Term Debt to Equity | 0.114 |
| Long-Term Debt to Total Capital | 0.114 |